<DOC>
	<DOCNO>NCT02200380</DOCNO>
	<brief_summary>This open-label , multicenter , prospective pilot study CDX-301 without plerixafor stem cell mobilizer allogeneic transplantation ( stem cell come another person ) . HLA-matched sibling healthy volunteer ( donor ) patient protocol specify hematologic malignancy ( recipient ) enrol .</brief_summary>
	<brief_title>A Safety Tolerability Study CDX-301 With Without Plerixafor Stem Cell Mobilization Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Donors : Read , understood provide write informed consent willing comply study requirement procedures 6 6 HLAmatched sibling Negative test human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C Both male female patient childbearing potential enrolled trial must use adequate birth control measure Subjects generally good health without significant medical condition , base upon prestudy medical history , physical examination , electrocardiogram ( ECG ) , chest X ray , laboratory test Meets criteria serve mobilize blood cell donor accordance applicable individual Transplant Center criteria Recipient : Read , understood provide write informed consent willing comply study requirement procedures 6 6 HLAmatched sibling Both male female patient childbearing potential enrolled trial must use adequate birth control measure Diagnosis one following : Acute Myelogenous Leukemia ( AML ) 1st remission beyond Acute Lymphoblastic Leukemia ( ALL ) 1st remission beyond Chronic Myelogenous Leukemia ( CML ) Chronic Lymphoblastic Leukemia ( CLL ) , relapse least one prior regimen Myelodysplastic Syndrome ( MDS ) , either intermediate 1,2 , high risk IPI Scoring System transfusion dependent NonHodgkins Lymphoma ( NHL ) Hodgkins Disease ( HD ) 2nd great complete remission , partial remission , relapse Meets criteria serve transplant recipient accordance applicable individual Transplant Center criteria Donors : Unwilling unable give inform consent , unable comply protocol include require followup test Prior treatment rhuFlt3L product Any vaccination within 4 week prior CDX301 dose Donation blood within 8 week , donation plasma within 2 week prior CDX301 dose Any experimental treatment within 4 week prior CDX301 dose Use systemic immunosuppressive agent ( exclude topical steroid ) within 12 month prior CDX301 dose . History first degree relative primary secondary immunodeficiency include type 1 diabetes , multiple sclerosis , rheumatoid arthritis , scleroderma psoriasis History tuberculosis infection Herpes zoster within 3 month prior start study drug Pregnant nursing Recipient : Unwilling unable give inform consent , unable comply protocol include require followup test Prior allogeneic transplant More one prior autologous transplant Prior treatment rhuFlt3L product Any vaccination within 4 week prior transplant Uncontrolled infection time transplant condition regimen Pregnant nursing Any condition , , opinion clinical investigator , would interfere evaluation study outcome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>